Cargando…

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

SIMPLE SUMMARY: Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in non-small cell lung cancer patients. These treatments are more effective the higher the expression of PD-L1 on tumor cells, reported as tumor proportion score. However, PD-L1 expression can be highly variable, dependi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamberti, Giuseppe, Sisi, Monia, Andrini, Elisa, Palladini, Arianna, Giunchi, Francesca, Lollini, Pier-Luigi, Ardizzoni, Andrea, Gelsomino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692442/
https://www.ncbi.nlm.nih.gov/pubmed/33114576
http://dx.doi.org/10.3390/cancers12113129
_version_ 1783614512693248000
author Lamberti, Giuseppe
Sisi, Monia
Andrini, Elisa
Palladini, Arianna
Giunchi, Francesca
Lollini, Pier-Luigi
Ardizzoni, Andrea
Gelsomino, Francesco
author_facet Lamberti, Giuseppe
Sisi, Monia
Andrini, Elisa
Palladini, Arianna
Giunchi, Francesca
Lollini, Pier-Luigi
Ardizzoni, Andrea
Gelsomino, Francesco
author_sort Lamberti, Giuseppe
collection PubMed
description SIMPLE SUMMARY: Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in non-small cell lung cancer patients. These treatments are more effective the higher the expression of PD-L1 on tumor cells, reported as tumor proportion score. However, PD-L1 expression can be highly variable, depending on different mechanisms of regulation. These mechanisms are usually grouped in intrisc (including genetic and epigenetic factors) and extrinsic factors (i.e., deriving from interaction of tumor cells with tumor microenvironment or other external factors). We reviewed mechanisms underlying PD-L1 expression regulation in order to provide a comprehensive overview and identify key regulatory factors that are or can potentially be exploited to improve outcomes on immune checkpoint inhibitors targeting the PD-1/PD-L1 axis. ABSTRACT: Treatment with inhibition of programmed cell death 1 (PD-1) or its ligand (PD-L1) improves survival in advanced non-small-cell lung cancer (NSCLC). Nevertheless, only a subset of patients benefit from treatment and biomarkers of response to immunotherapy are lacking. Expression of PD-L1 on tumor cells is the primary clinically-available predictive factor of response to immune checkpoint inhibitors, and its relevance in cancer immunotherapy has fostered several studies to better characterize the mechanisms that regulate PD-L1 expression. However, the factors associated with PD-L1 expression are still not well understood. Genomic alterations that activate KRAS, EGFR, and ALK, as well as the loss of PTEN, have been associated with increased PD-L1 expression. In addition, PD-L1 expression is reported to be increased by amplification of CD274, and decreased by STK11 deficiency. Furthermore, PD-L1 expression can be modulated by either tumor extrinsic or intrinsic factors. Among extrinsic factors, the most prominent one is interferon-γ release by immune cells, while there are several tumor intrinsic factors such as activation of the mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Myc pathways that can increase PD-L1 expression. A deeper understanding of PD-L1 expression regulation is crucial for improving strategies that exploit inhibition of this immune checkpoint in the clinic, especially in NSCLC where it is central in the therapeutic algorithm. We reviewed current preclinical and clinical data about PD-L1 expression regulation in NSCLC.
format Online
Article
Text
id pubmed-7692442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76924422020-11-28 The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players? Lamberti, Giuseppe Sisi, Monia Andrini, Elisa Palladini, Arianna Giunchi, Francesca Lollini, Pier-Luigi Ardizzoni, Andrea Gelsomino, Francesco Cancers (Basel) Review SIMPLE SUMMARY: Immunotherapy against PD-1/PD-L1 dramatically improved outcomes in non-small cell lung cancer patients. These treatments are more effective the higher the expression of PD-L1 on tumor cells, reported as tumor proportion score. However, PD-L1 expression can be highly variable, depending on different mechanisms of regulation. These mechanisms are usually grouped in intrisc (including genetic and epigenetic factors) and extrinsic factors (i.e., deriving from interaction of tumor cells with tumor microenvironment or other external factors). We reviewed mechanisms underlying PD-L1 expression regulation in order to provide a comprehensive overview and identify key regulatory factors that are or can potentially be exploited to improve outcomes on immune checkpoint inhibitors targeting the PD-1/PD-L1 axis. ABSTRACT: Treatment with inhibition of programmed cell death 1 (PD-1) or its ligand (PD-L1) improves survival in advanced non-small-cell lung cancer (NSCLC). Nevertheless, only a subset of patients benefit from treatment and biomarkers of response to immunotherapy are lacking. Expression of PD-L1 on tumor cells is the primary clinically-available predictive factor of response to immune checkpoint inhibitors, and its relevance in cancer immunotherapy has fostered several studies to better characterize the mechanisms that regulate PD-L1 expression. However, the factors associated with PD-L1 expression are still not well understood. Genomic alterations that activate KRAS, EGFR, and ALK, as well as the loss of PTEN, have been associated with increased PD-L1 expression. In addition, PD-L1 expression is reported to be increased by amplification of CD274, and decreased by STK11 deficiency. Furthermore, PD-L1 expression can be modulated by either tumor extrinsic or intrinsic factors. Among extrinsic factors, the most prominent one is interferon-γ release by immune cells, while there are several tumor intrinsic factors such as activation of the mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK) and Myc pathways that can increase PD-L1 expression. A deeper understanding of PD-L1 expression regulation is crucial for improving strategies that exploit inhibition of this immune checkpoint in the clinic, especially in NSCLC where it is central in the therapeutic algorithm. We reviewed current preclinical and clinical data about PD-L1 expression regulation in NSCLC. MDPI 2020-10-26 /pmc/articles/PMC7692442/ /pubmed/33114576 http://dx.doi.org/10.3390/cancers12113129 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lamberti, Giuseppe
Sisi, Monia
Andrini, Elisa
Palladini, Arianna
Giunchi, Francesca
Lollini, Pier-Luigi
Ardizzoni, Andrea
Gelsomino, Francesco
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title_full The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title_fullStr The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title_full_unstemmed The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title_short The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
title_sort mechanisms of pd-l1 regulation in non-small-cell lung cancer (nsclc): which are the involved players?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692442/
https://www.ncbi.nlm.nih.gov/pubmed/33114576
http://dx.doi.org/10.3390/cancers12113129
work_keys_str_mv AT lambertigiuseppe themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT sisimonia themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT andrinielisa themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT palladiniarianna themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT giunchifrancesca themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT lollinipierluigi themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT ardizzoniandrea themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT gelsominofrancesco themechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT lambertigiuseppe mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT sisimonia mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT andrinielisa mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT palladiniarianna mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT giunchifrancesca mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT lollinipierluigi mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT ardizzoniandrea mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers
AT gelsominofrancesco mechanismsofpdl1regulationinnonsmallcelllungcancernsclcwhicharetheinvolvedplayers